Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPulmonologyModa Health benralizumab Coverage Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentModa HealthPolicy IC-0347

    Benralizumab (Fasenra) subcutaneous injection — Coverage Criteria

    Customize your policy alerts

    Sign up for Moda Health Policy IC-0347 alerts

    Get alerted when Policy IC-0347 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs coverage and authorization criteria for subcutaneous benralizumab (Fasenra) for severe eosinophilic asthma and select eosinophilic pulmonary diagnoses for Moda Health members in North Carolina.

    Policy Summary
    PayerModa Health
    PolicyBenralizumab (Fasenra) subcutaneous injection — Coverage Criteria
    Policy CodePolicy IC-0347
    Change TypeNo material change
    Effective DateOct 3, 2023
    Last ReviewOct 3, 2023
    Next Review DateOct 3, 2023
    Key ActionObtain prior authorization; submit HCPCS J0517 with clinical documentation to authorize 6 months of coverage (loading then maintenance dosing per policy).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial authorization period
    30 mgdose per administration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    every 8 weeksmaintenance interval
    ≥150 cells/µLeosinophil threshold
    ≥2required prior-year exacerbations

    Coverage and Medical Necessity Criteria

    Initial Approval - Severe Eosinophilic Asthma

    Covered when ALL of the following are met:

    Age: Patient is at least 12 years of age
    Concurrent biologics: Will not be used in combination with other anti-IgE, anti-IL4, anti-IL5, or IgG2 lambda monoclonal antibody agents

    Examples: omalizumab, mepolizumab, reslizumab, dupilumab, tezepelumab

    Excluded uses: Must NOT be used for treatment of other eosinophilic conditions or for relief of acute bronchospasm/status asthmaticus

    Examples: allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome

    Severity: Patient must have severe asthma

    See definitions for components of severe disease

    Phenotype: Asthma with eosinophilic phenotype indicated by blood eosinophils ≥150 cells/µL within 6 weeks of dosing≥150 cells/µL within 6 weeks
    Background therapy: Used as add-on maintenance treatment in patients regularly receiving BOTH: medium- to high-dose inhaled corticosteroids AND an additional controller medication

    Additional controller examples: long-acting beta agonist, leukotriene modifiers

    Exacerbation history: Two or more exacerbations in the previous year requiring daily oral corticosteroids for at least 3 days (in addition to regular maintenance therapy)≥2 exacerbations
    Baseline measurement of at least one of: systemic corticosteroid use, inhaled corticosteroid use, number of hospitalizations/ER/unscheduled visits due to condition, or FEV1

    For assessment of clinical status

    Renewal Criteria

    Renewal provided when ALL of the following are met:

    Continued criteria: Patient continues to meet the universal and indication-specific criteria identified for initial approval
    Toxicity: Absence of unacceptable toxicity from the drug

    Examples: parasitic (helminth) infection, severe hypersensitivity such as anaphylaxis, angioedema, urticaria, rash

    Clinical improvement: Demonstrated improvement in asthma symptoms or exacerbations as evidenced by a decrease in systemic corticosteroid use; OR two-fold or greater decrease in inhaled corticosteroid use for at least 3 days; OR reduction in hospitalizations, ER visits, or unscheduled visits; OR improvement from baseline in FEV1

    Either clinical event reduction OR FEV1 improvement required

    Benralizumab must not be used for the treatment of other eosinophilic conditions beyond the covered indications. Examples of excluded eosinophilic disorders include allergic bronchopulmonary aspergillosis/mycosis (ABPA), Churg–Strauss syndrome (eosinophilic granulomatosis with polyangiitis), and hypereosinophilic syndrome. The policy also excludes use for relief of acute bronchospasm or status asthmaticus.

    Benralizumab will not be covered when used in combination with other monoclonal biologic therapies that target IgE, IL‑4, IL‑5, or are IgG2 lambda antibodies. Examples include omalizumab, mepolizumab, reslizumab, dupilumab, and tezepelumab. Use of benralizumab for excluded indications or in combination with these listed biologics is considered not medically necessary.

    Coding and Diagnosis Codes

    Covered HCPCS CodesHCPCSCovered
    J0517Injection, benralizumab, 1 mg
    NDCNDC
    00310-1730-xxFasenra 30 mg/mL single-dose prefilled syringe NDC
    00310-1830-xxFasenra 30 mg/mL single-dose autoinjector (FASENRA PEN) NDC
    Covered Diagnosis Codes (Appendix 1)ICD-10Covered
    J45.50Severe persistent asthma, uncomplicated
    J82.81Eosinophilic pneumonia, NOS
    J82.82Acute eosinophilic pneumonia
    J82.83Eosinophilic asthma
    J82.89Other pulmonary eosinophilia, not elsewhere classified
    inv-08: Blood eosinophil count
    Required thresholdBlood eosinophils ≥150 cells/µL
    Timing relative to dosingMeasured within 6 weeks of dosing
    ContextIndicates eosinophilic phenotype required for severe asthma indication

    Provider Requirements, Prior Authorization, and Billing

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benralizumab (IC-0347). Initial authorization is provided for 6 months and may be renewed if renewal criteria are met. Submit documentation that supports the clinical criteria (age, eosinophil count, maintenance therapy, and exacerbation history).

    • Prior authorization required (initial approval up to 6 months)
    • Include clinical documentation: age, recent blood eosinophil count (≥150 cells/µL within 6 weeks), current maintenance therapy (medium–high dose inhaled corticosteroid AND additional controller), exacerbation history (≥2 exacerbations in past year requiring systemic steroids ≥3 days)
    • HCPCS: J0517 — Injection, benralizumab, 1 mg
    Documentation Required

    Background Controller Therapy Required

    Benralizumab must be used as add-on maintenance therapy in patients who are regularly receiving BOTH a medium to high-dose inhaled corticosteroid and an additional controller medication (for example, a long-acting beta agonist or leukotriene modifier).

    Background and Mechanism

    Benralizumab is a monoclonal antibody directed against the interleukin‑5 receptor pathway used as an add‑on maintenance therapy for severe eosinophilic asthma. It is intended to reduce blood eosinophil counts and improve control in patients with an eosinophilic asthma phenotype who remain uncontrolled despite high‑intensity inhaled therapy.

    Key Definitions

    inv-15: Severe asthma
    Core requirementPatient must have severe asthma (see components of severity)
    Eosinophilic phenotypeAsthma with blood eosinophils ≥150 cells/µL within 6 weeks of dosing
    Background therapyRegularly receiving both medium- to high-dose inhaled corticosteroid AND an additional controller medication
    Exacerbation historyTwo or more exacerbations in the previous year requiring daily oral corticosteroids for at least 3 days
    Baseline assessmentBaseline measurement of at least one: systemic corticosteroid use, inhaled corticosteroid use, number of hospitalizations/ER/unscheduled visits, or FEV1
    Severity components (examples)Symptoms throughout the day; frequent nighttime awakenings; frequent SABA use; very limited activities; FEV1 percent predicted <60%; frequent/intense exacerbations
    Policy Summary
    PayerModa Health
    PolicyBenralizumab (Fasenra) subcutaneous injection — Coverage Criteria
    Policy CodePolicy IC-0347
    Change TypeNo material change
    Effective DateOct 3, 2023
    Last ReviewOct 3, 2023
    Next Review DateOct 3, 2023
    Key ActionObtain prior authorization; submit HCPCS J0517 with clinical documentation to authorize 6 months of coverage (loading then maintenance dosing per policy).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding and Diagnosis CodesProvider Requirements, Prior Authorization, and BillingBackground and MechanismKey Definitions
    • Required background therapy: medium–high dose inhaled corticosteroid + an additional controller agent
    Denial Risk

    Concurrent Biologic Therapy Prohibited

    Benralizumab must NOT be used concurrently with other biologic therapies targeting IgE, IL-4, IL-5, or related pathways. Requests indicating concurrent use will be denied.

    • Concurrent biologics that preclude approval: omalizumab, mepolizumab, reslizumab, dupilumab, tezepelumab, and other anti-IgE/anti-IL4/anti-IL5 monoclonal antibodies